Joshua A. Kazam
Co-Founder & DirectorMr. Joshua A. Kazam, also known as Josh, is Member of Advisory Board of MedPod, Inc. Mr. Kazam has B.A. in Economics, Entrepreneurial Management, Finance from University of Pennsylvania - The Wharton School. Mr. Joshua A. Kazam, also known as Josh, was an Independent Director at Screaming Eagle Acquisition Corp. since January 2022 until May 2024. He serves as Director at MedPod, Inc. Mr. Kazam had been Independent Director at Soaring Eagle Acquisition Corp. since February 23, 2021 until September 2021. Mr. Kazam served as Independent Director at Tishman Speyer Innovation Corp. II since February 11, 2021 until December 2022. Mr. Kazam serves as Co-Founder and Director of Vida Ventures. He is Co-Founder of Kronos Bio, Inc. and had been its Director since June 2017 until June 2025. Mr. Kazam is a Co-Founder of Allogene Therapeutics, Inc. and has been its Director since November 2017. He had been an Independent Director of Flying Eagle Acquisition Corp. from February 2020 until December 2020. He also served as an Independent Director of TS Innovation Acquisitions Corp. since November 9, 2020 until June 2021. He serves as Director at Breakthrough Properties, Limited Liability Company and Breakthrough Services LLC since April 2019. In June 2009, Mr. Kazam is a co-founder of Two River Consulting, LLC and has been its Partner since 2004. He served as President and Chief Executive Officer of IconOVir Bio, Inc. He serves as a Director of Investments at Paramount Capital Asset Management, Inc. Mr. Kazam had been a Director of Platinum Eagle Acquisition since January 11, 2018 until March 2019. Mr. Kazam co-founded Kirax Corporation in 2005 and serves as its Secretary. He Co-Founded Kite Pharma, Inc. and served as its President until September 2010. He serves as a director of IconOVir Bio, Inc. since August 2018. He served as Chief Executive Officer and President of Nile Therapeutics, Inc. from June 11, 2009 to August 2012. He had been on the Board of Directors of Capricor Therapeutics Inc. (CAPR) from August 2005 to May 2019. He served as President of Allogene Therapeutics Inc. from November 2017 to June 2018. He was a Co-Founder of Nile Therapeutics, Inc. He served as the Managing Director of Paramount BioCapital, Inc., where he was responsible for ongoing operations of venture investments. Mr. Kazam serves as a Director of Vision Path, Incorporated (d/b/a Hubble Contacts) since May 2016 and ByHeart, Inc. since November 2016. He was previously employed at Paramount Capital Investments L.L.C. Prior to that, Mr. Kazam was employed at a venture capital firm specializing in biotechnology investments, from July 1999 to September 2004, where he served as the Managing Director and was responsible for ongoing operations of venture investments. He served as Vice President at Manhattan Pharmaceuticals, Inc. He serves as a Director of Danube Pharmaceuticals, Inc. He is a Director of Baby Generation, Inc., Second Science and Veterinary Prime, Inc. He was Director of Investments Management at Orion Biomedical Fund, L.P. from 2002 to 2004. He serves as a Director of several privately held companies, including Kirax Corporation and Cortiva Education. Joshua is a Penn Medicine Trustee. Mr. Kazam is a Member of the Wharton School’s Undergraduate Executive Board and serves on the Board of Directors of the Desert Flower Foundation since June 2016. Mr. Kazam has been a Director of Vetprime, Velcera, Inc. since May 2004. He has served as an Officer and Director of Riverbank Capital Securities, Inc. since October 2005. He served as Managing Director of a life science focused venture capital firm from 1999 to 2004. He served as a Director of Kite Pharma, Inc. since June 2009 until October 2, 2017. Where he served on the Board of Directors from inception until its acquisition by Gilead Sciences, Inc. in 2017. He served as a Director of Arno Therapeutics, Inc. until September 2010. He served as a Director of Manhattan Pharmaceuticals Inc. from February 2003 to September 14, 2005. Joshua is an advisor to Symbiotic Capital. Joshua also serves as a director of several privately held companies including ByHeart Inc. He served as the Director of Manhattan Research Development since December 2001 and Nile Therapeutics, Inc. since August 2005. He had been an Independent Director of Diamond Eagle Acquisition Corp. since May 2019 until April 2020. He is a co-founder of 76Bio, Inc.
Positions
- Company NameAllogene Therapeutics, Inc.Stock CodeALLOPositionCo-Founder & Director
